Loading…
Latigo Biotherapeutics, Inc.
Latigo Biotherapeutics, Inc. (LTGO) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Thousand Oaks, United States and has 66 employees. The company is worth $928.19M. Revenue was $0 in fiscal 2025. It reported a net loss of $109.17M. The share price is 46.0% below its 52-week high of $25.93. None of the 38 superinvestors we track reported it in their latest 13F. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in LTGO.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| QDELQuidelOrtho Corp | $13.48 | — | 0.5x | 0.00% | -45.91% | $924.4M |
| CGEMCullinan Therapeutics, Inc. | $14.92 | — | 3.0x | 0.00% | -50.30% | $916.95M |
| SVRASavara Inc | $4.45 | — | 7.9x | 0.00% | -105.48% | $914.3M |
| RIGLRigel Pharmaceuticals Inc | $48.86 |
| 2.9x |
| 2.1x |
| 0.00% |
| 126.90% |
| $912.7M |
| VSTMVerastem, Inc. | $10.06 | — | 18.2x | 0.00% | -471.16% | $911.07M |
| BVSBioventus Inc. | $13.30 | 17.1x | 4.0x | 0.00% | 25.68% | $908.46M |